The drug price short

Episode Summary

Executive Summary: The episode centers on U.S. pharmaceutical pricing, arguing that high brand-name drug prices are sustained not only by R&D costs and patents but also by branding, patient steering, patent tactics, regulatory gaps, and a fragmented reimbursement system. It highlights how generics don’t always fully displace brands and how middlemen and policy design shape who captures drug revenues.

Main Topics: Myth of post-patent price collapse (Priority: 5/5): The conversation tests the industry claim that prices must stay high before patent expiry because of heavy R&D costs, and finds that many brands keep a profitable long tail even after generics arrive. Branding and patient pressure in drug choice (Priority: 5/5): Direct-to-consumer advertising and fear-based messaging can keep patients and doctors attached to branded drugs even when generics are available. Patent gamesmanship and exclusivity extension (Priority: 5/5): Drugmakers use tactics like pay-for-delay, evergreening, and product reformulations to extend market protection and delay generic entry. EpiPen as a case study in U.S. pricing (Priority: 5/5): Mylan’s steep EpiPen increase illustrates how device patents, limited competition, and middlemen can drive prices up without corresponding changes to the underlying drug. Middlemen and opaque pricing flows (Priority: 4/5): A large share of the final price may go to PBMs, distributors, and pharmacists rather than the manufacturer, making U.S. drug pricing a black box. Regulatory and patent design distort incentives (Priority: 4/5): Patent timing, FDA review backlogs, and exclusivity rules can skew investment toward profitable late-stage treatments and delay competition. Cancer drugs and payer tolerance (Priority: 4/5): Payers are more likely to tolerate high prices for cancer drugs because of survival benefits and the difficulty of denying treatment in life-threatening cases.

Key Arguments: Brand drug prices do not simply fall to generic levels after patent expiry; a persistent branded niche can keep prices high. Direct-to-consumer pharma marketing in the U.S. helps sustain demand for brands and is unusual among developed countries. Some branded drugs continue to be prescribed because doctors and patients believe inactive ingredients or formulation changes matter. Pharma companies use legal and semi-legal tactics to extend market exclusivity, including pay-for-delay settlements and minor reformulations. Mylan’s EpiPen price hikes were not mirrored one-for-one in company profits, suggesting the pricing system funnels money to intermediaries. The U.S. regulatory structure, including FDA backlog and limited competition, slows generic entry and weakens price discipline. Patent and exclusivity design can unintentionally favor late-stage cancer research over preventive or early-stage drugs. Payers are more willing to absorb high prices for innovative cancer drugs than for less urgent treatments, shaping investment incentives.

Data Points: Generic price reduction: up to 98% lower - Generic drugs can undercut brand-name drugs dramatically after patent expiry. Prozac brand price: $16 a pill - Brand-name Prozac (Lilly) was cited as still selling at this level despite generics being available for cents. Fluoxetine generic price: a few cents a pill - The generic version of Prozac was cited as costing only pennies. EpiPen price increase: about $100 to $600 - Two EpiPens reportedly rose from roughly $100 in 2007 to about $600 by the time discussed. EpiPen dosage value: about a dollar’s worth of drugs - The underlying medication in the device is inexpensive; the device and patent protection drive the price. Mylan price hike: 5,000% overnight - Referenced in the Martin Shkreli comparison to show why his move drew outrage. Exclusivity window: 5 to 7 years - After a drug starts selling, FDA-granted exclusivity provides additional protection beyond patents. Drug marketing geography: 1 developed country besides the U.S. - New Zealand was cited as the only other developed country allowing direct-to-consumer drug advertising.

Pivotal Quotes: "There is this sticky set of consumers and doctors who still want the brand, and the price of the brand keeps going up." — David Crowe: Explaining why brand-name prices can remain high even after generic alternatives enter the market. "There are geopolitical and regulatory pressures that healthcare providers have." — Pam Joshi: From the teaser for The Next Five podcast, connecting boardroom risk with healthcare sector pressures. "Data and analytics can strengthen your ability to manage risk by identifying your vulnerabilities early." — Sean McGovern: From the teaser for The Next Five podcast, highlighting risk management through analytics.

Implications: Listeners should expect drug pricing to remain politically contentious because it is driven by patents, regulation, branding, and intermediaries—not just R&D. Reform likely needs to address market structure and transparency, not only manufacturer behavior.